Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.

OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint.

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment.

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

Velocity Clinical Research partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials ...

The UK MHRA has granted approval for Cybin to initiate the EMBRACE study to assess CYB003 for the adjunctive treatment of MDD.

SPRIM PRO and ObvioHealth have announced an expansion of their partnership to provide a fully integrated trial solution.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials.